Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet (London, England). 2009;374:1371–1382.
   PubMed Web of Science ®Google Scholar
• Stordal B, Hamon M, McEneaney V, et al. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One. 2012;7:e40717.
   PubMed Web of Science ®Google Scholar
• Park MJ, Park IC, Bae IJ, et al. Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. Int J Oncol. 2003;22:1271–1276.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Seymour JF. Role of arsenic trioxide in acute promyelocytic leukemia. Curr Treat Options Oncol. 2013;14:170–184.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Tricot G, Desikan R, et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 2002;16:1835–1837.
   PubMed Web of Science ®Google Scholar
• Chang HS, Bae SM, Kim YW, et al. Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: relation to the apoptosis molecular pathway. Int J Oncol. 2007;30:1129–1135.
   PubMed Web of Science ®Google Scholar
• Cornelison R, Dobbin ZC, Katre AA, et al. Targeting RNA-polymerase I in Both chemosensitive and chemoresistant populations in epithelial ovarian cancer. Clin Cancer Res. 2017;23:6529–6540.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res. 2010;70:440–446.
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–681.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111:273–279.
   PubMed Web of Science ®Google Scholar
• Horwitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;15:55–61.
   PubMedGoogle Scholar
• Haber M, Burkhart CA, Regl DL, et al. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem. 1995;270:31269–31275.
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997;272:17118–17125.
   PubMed Web of Science ®Google Scholar
• Sherman-Baust CA, Becker KG, Wood Iii WH, et al. Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res. 2011;4:21.
   PubMed Web of Science ®Google Scholar
• Jeanne M, Lallemand-Breitenbach V, Ferhi O, et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010;18:88–98.
   PubMed Web of Science ®Google Scholar
• Jadhav V, Ray P, Sachdeva G, et al. Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21(WAF1/CIP1) expression via epigenetic remodeling in LNCaP and PC3 cell lines. Life Sci. 2016;1;148:41–52.
   Web of Science ®Google Scholar
• Ling YH, Jiang JD, Holland JF, et al. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol. 2002;62:529–538.
   PubMed Web of Science ®Google Scholar
• Nagappan A, Lee WS, Yun JW, et al. Tetraarsenic hexoxide induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt suppression and p38 MAPK activation in SW620 human colon cancer cells. PLoS One. 2017;12:e0174591.
   PubMed Web of Science ®Google Scholar
• Lee WS, Yun JW, Nagappan A, et al. Tetraarsenic hexoxide demonstrates anticancer activity at least in part through suppression of NF-kappaB activity in SW620 human colon cancer cells. Oncol Rep. 2015;33:2940–2946.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6:203–208.
   PubMed Web of Science ®Google Scholar
• Hu Q, Peng J, Liu W, et al. Elevated cleaved caspase-3 is associated with shortened overall survival in several cancer types. Int J Clin Exp Pathol. 2014;7:5057–5070.
   PubMed Web of Science ®Google Scholar
• Safa M, Mousavizadeh K, Noori S, et al. cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis. Eur J Pharmacol. 2014;736:115–123.
   PubMed Web of Science ®Google Scholar
• Xiong X, Li Y, Liu L, et al. Arsenic trioxide induces cell cycle arrest and affects Trk receptor expression in human neuroblastoma SK-N-SH cells. Biol Res. 2018;51:18.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007;7:216–223.
   PubMed Web of Science ®Google Scholar
• Zoli W, Ricotti L, Tesei A, et al. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol/Hematol. 2001;37:69–82.
   PubMed Web of Science ®Google Scholar
• Soriano AF, Helfrich B, Chan DC, et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999;59:6178–6184.
   PubMed Web of Science ®Google Scholar
• Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354–3360.
   PubMed Web of Science ®Google Scholar
• Helm CW, States JC. Enhancing the efficacy of cisplatin in ovarian cancer treatment: could arsenic have a role. J Ovarian Res. 2009;2:2.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Wang F, Zhao Z, et al. BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells. PLoS One. 2011;6:e20586.
   PubMed Web of Science ®Google Scholar
• Luo D, Zhang X, Du R, et al. Low dosage of arsenic trioxide (As2O3) inhibits angiogenesis in epithelial ovarian cancer without cell apoptosis. J Biol Inorg Chem. 2018;23:939–947.
   PubMed Web of Science ®Google Scholar
• Chung WH, Sung BH, Kim SS, et al. Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int J Oncol. 2009;34:1669–1679.
   PubMed Web of Science ®Google Scholar